Merck Plans to Move Global Headquarters within New Jersey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Plans to Move Global Headquarters within New Jersey



Merck & Co. has announced plans to relocate the company’s global headquarters within the state of New Jersey (NJ), with the transition expected to begin in 2014 and be completed by mid-2015, according to an Oct. 9, 2012, press release. The company will close its current headquarters building in Whitehouse Station, NJ, where it has been since 1992, and move the headquarters less than 30 miles to the northeast to its existing property in Summit, NJ. The Summit facility currently houses 1800 people in research, manufacturing, animal health, and consumer care operations. About 2000 employees and contractors currently working in Whitehouse Station will move to the Summit location or to other nearby facilities such as those in Branchburg, NJ and Cokesbury, NJ.

The headquarters relocation is part of the company's ongoing program to consolidate its global real estate footprint and lower its annual operating expenses. The Summit location was selected because it is a multiuse site with excess workspace capacity and is near major transportation hubs and urban centers, said the company in the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here